Rapport Therapeutics (RAPP) CMO awarded 130,000 stock options at $27.75

Rhea-AI Filing Summary

Rapport Therapeutics reported that Chief Medical Officer Jeffrey Sevigny received a grant of stock options on February 2, 2026. The award covers 130,000 stock options to purchase common stock at an exercise price of $27.75 per share, expiring on February 2, 2036.

The options vest in 48 equal monthly installments starting after January 1, 2026, and require Dr. Sevigny’s continued service on each vesting date. After this grant, he beneficially owns 130,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sevigny Jeffrey

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.75	02/02/2026		A		130,000		(1)	02/02/2036	Common Stock	130,000	$0	130,000	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Troy Ignelzi, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rapport Therapeutics (RAPP) report for Jeffrey Sevigny?

Rapport Therapeutics reported a stock option grant to Chief Medical Officer Jeffrey Sevigny. He received 130,000 options to buy common stock at an exercise price of $27.75 per share, awarded on February 2, 2026, as part of his compensation package.

How many stock options did the CMO of Rapport Therapeutics receive?

Chief Medical Officer Jeffrey Sevigny received 130,000 stock options. These options give him the right to purchase 130,000 shares of Rapport Therapeutics common stock at a fixed exercise price of $27.75 per share, subject to the specified vesting schedule and continued service.

What is the exercise price and term of the Rapport Therapeutics CMO options?

The stock options granted to the CMO have an exercise price of $27.75 per share and expire on February 2, 2036. This means he can buy shares at $27.75 any time after vesting and before the February 2, 2036 expiration date, if he chooses to exercise.

How do the Jeffrey Sevigny stock options at Rapport Therapeutics vest?

The options vest in forty-eight equal monthly installments following January 1, 2026. Each month, one forty-eighth of the 130,000 options becomes exercisable, as long as Jeffrey Sevigny continues his service with Rapport Therapeutics on each applicable vesting date.

What is Jeffrey Sevigny’s beneficial ownership after this Form 4 transaction?

After the reported transaction, Jeffrey Sevigny beneficially owns 130,000 derivative securities in the form of stock options. All of these options are held directly, and their exercisability depends on the monthly vesting schedule tied to his continued service with the company.